ReviewCancer letters2013
Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.
Review in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Array comparative genomic hybridisation in haematological malignancies: A comprehensive review.African journal of laboratory medicine · 2026Review
- The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- AirLab: a cloud-based platform to manage and share antibody-based single-cell research.Genome biology · 2016Article
- Challenges of deciphering gastric cancer heterogeneity.World journal of gastroenterology · 2015Review
- The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Reverse phase protein arrays: mapping the path towards personalized medicine.Molecular diagnosis & therapy · 2014Review
- Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.Genome biology · 2014Article
- An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa.World journal of gastroenterology · 2014Review
- Quantitative imaging in cancer evolution and ecology.Radiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Advances in cancer genomics have been propelled by the steady evolution of molecular profiling technologies. Over the past decade, high-throughput sequencing technologies have matured to the point necessary to support disease-specific shotgun sequencing. This has compelled whole-genome sequencing studies across a broad panel of malignancies. The emergence of high-throughput sequencing technologies has inspired new chemical and computational techniques enabling interrogation of cancer-specific genomic and transcriptomic variants, previously unannotated genes, and chromatin structure. Finally, recent progress in single-cell sequencing holds great promise for studies interrogating the consequences of tumor evolution in cancers presenting with genomic heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.